APA (7th ed.) Citation

Kawamura, Y., Akuta, N., Shindoh, J., Matsumura, M., Okubo, S., Tominaga, L., . . . Kumada, H. (2025). Peripheral blood CD4+/CD8+ T cell ratio may have potential for predicting the treatment response of durvalumab plus tremelimumab therapy (STRIDE) for unresectable hepatocellular carcinoma: Preliminary report. Hepatology Research, 55(6), 948. https://doi.org/10.1111/hepr.14188

Chicago Style (17th ed.) Citation

Kawamura, Yusuke, et al. "Peripheral Blood CD4+/CD8+ T Cell Ratio May Have Potential for Predicting the Treatment Response of Durvalumab Plus Tremelimumab Therapy (STRIDE) for Unresectable Hepatocellular Carcinoma: Preliminary Report." Hepatology Research 55, no. 6 (2025): 948. https://doi.org/10.1111/hepr.14188.

MLA (9th ed.) Citation

Kawamura, Yusuke, et al. "Peripheral Blood CD4+/CD8+ T Cell Ratio May Have Potential for Predicting the Treatment Response of Durvalumab Plus Tremelimumab Therapy (STRIDE) for Unresectable Hepatocellular Carcinoma: Preliminary Report." Hepatology Research, vol. 55, no. 6, 2025, p. 948, https://doi.org/10.1111/hepr.14188.